Last updated: February 13, 2026
What Is the Drug and Its Approved Use?
The National Drug Code (NDC) 00173-0873 corresponds to Vyndaqel (tafamidis meglumine), a drug approved by the FDA in May 2019 for treating transthyretin amyloid cardiomyopathy (ATTR-CM). It is prescribed to slow disease progression in adult patients.
Current Market Size and Demand
Prevalence of ATTR-CM
- Estimated at 10,000–20,000 patients in the U.S. (Papers: 2020).
- Increasing due to improved diagnostics and awareness.
- Diagnosed cases: roughly 6,000 in the U.S. (2022 estimate).
Market Penetration and Reimbursement
- Vyndaqel is covered under Medicare and private insurance plans.
- Initial market penetration remains limited, approximately 15–20% of diagnosed patients (2022–2023 data).
- The drug's cost is a significant factor influencing adoption.
Competitive Landscape
Key Competitors
- Inotersen (Tegsedi) for hereditary transthyretin amyloidosis with polyneuropathy.
- Patisiran (Onpattro) for hereditary transthyretin amyloidosis with polyneuropathy.
- Other emerging agents: Next-generation TTR stabilizers, gene-silencing therapies.
Market Differentiation
- Vyndaqel is the only TTR stabilizer approved specifically for cardiomyopathy.
- Patisiran and Inotersen target neuropathy, not cardiac manifestations.
- Innovations for targeted gene silencing could threaten Vyndaqel's market share.
Price History and Current Pricing
Initial Pricing (2019)
- Approximate wholesale acquisition cost (WAC): $175,000 per year per patient (per reports from 2019).
Adjustments Over Time
- Slight price increases of 2-4% annually driven by inflation and manufacturing costs.
- Price cap set by payer negotiations and insurance coverage policies.
Current Price Approximation (2023)
- WAC: around $180,000–$185,000 annually.
Price Projection Analysis
Factors Influencing Future Pricing
- Market expansion: As diagnostic rates improve, patient volume increases, potentially allowing for price stabilization or reduction to improve access.
- Reimbursement policies: Payer negotiations and CMS adjustments could pressurize prices downward.
- Competitor entry: Introduction of alternative therapies or generics could lead to price erosion.
- Regulatory decisions: New indications or combination therapies may impact the drug’s pricing.
Projected Trends (2024–2028)
| Year |
Estimated WAC (USD) |
Key Drivers |
| 2024 |
$185,000 |
Market penetration increases, moderate inflation |
| 2025 |
$185,000–$190,000 |
Payer negotiations tighten, potential entry of generics |
| 2026 |
~$190,000 |
Slight price stabilization, increased competition |
| 2027 |
$180,000–$185,000 |
Entry of biosimilars or cheaper alternatives, price caps |
| 2028 |
~$180,000 |
Market maturity, stabilized pricing |
Revenue and Market Share Estimate
-
U.S. Market Revenue (2023):
Approximate annual revenue = 6,000 diagnosed patients × 20% market penetration × $180,000 = $216 million.
-
Global Market:
Assuming similar penetration rates, a potential global revenue estimate can range between $300 million and $500 million by 2025, considering expanding indications and increasing diagnosis.
Key Challenges and Opportunities
Challenges:
- Slow diagnosis rates limit market size expansion.
- Pricing pressures from payers.
- Emerging therapies threatening market share.
Opportunities:
- Expanding indications to early-stage disease.
- Increasing diagnosis rates via screening programs.
- Developing combination therapies to enhance efficacy and justify premium pricing.
Key Takeaways
- Vyndaqel's annual price remains around $180,000 to $185,000 in 2023.
- The U.S. market generates roughly $216 million annually, with global opportunities potentially exceeding $300 million.
- Competition from alternative therapies and payer negotiations are key factors influencing future pricing.
- Market growth depends on improved diagnosis and expanded indications.
- Price erosion could occur from biosimilar entry starting after patent exclusivity expiration (expected around 2032).
Frequently Asked Questions
1. What are the main factors driving the price of Vyndaqel?
Market penetration, manufacturing costs, negotiations with payers, and competition influence Vyndaqel’s price.
2. How might new therapies affect Vyndaqel’s market share?
Emerging gene-silencing drugs could offer alternatives, potentially reducing Vyndaqel’s market share and pressure prices downward.
3. What is the patent status of Vyndaqel?
Patent protection extends likely into the early 2030s, delaying biosimilar entry and price erosion.
4. How does diagnosis rate impact market size?
Low diagnosis rates limit expansion; increasing awareness and screening could significantly grow the market.
5. Are there regulatory or policy factors that could affect future pricing?
Yes. Payer policies, reimbursement reforms, and value-based pricing models could all influence the drug's cost over time.
References
[1] IQVIA, 2022. U.S. pharmaceutical market reports.
[2] FDA, 2019. Vyndaqel approval announcement.
[3] Published clinical papers on ATTR-CM prevalence.
[4] Industry analyst estimates, 2023.
